TuesdayMar 18, 2025 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Demonstrates Quantum Supremacy on a Real-World Problem

D-Wave has shown quantum computational supremacy on a useful, real-world problem, a first in the industry, highlighting the potential of quantum computing for materials discovery and complex simulations beyond classical computational limits. A peer-reviewed paper published in Science validates that D-Wave’s annealing quantum computer solved a magnetic materials simulation problem that is beyond the capabilities of classical supercomputers. The simulation, which took minutes to solve on D-Wave’s system, would require nearly one million years and more electricity than the world’s annual consumption on a GPU-based supercomputer. The Advantage2 annealing quantum computer prototype was used to achieve this milestone and is…

Continue Reading

FridayMar 07, 2025 10:45 am

D-Wave Quantum Inc. (NYSE: QBTS), Staque Develop Hybrid Quantum Application to Optimize Autonomous Agriculture Vehicles

The companies expect the application to accelerate autonomy in agriculture, streamlining agricultural operations. The technology aims to enhance efficiency in large-scale farming by providing real-time optimization solutions. The initiative is part of a broader strategic partnership between D-Wave and Staque to accelerate commercial adoption of annealing quantum computing. D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, and the first supplier of production-grade quantum computers, and Staque, a leading consulting and development practice in AI, blockchain and quantum computing, collaborated to develop a hybrid-quantum system designed to optimize the movements of autonomous agricultural vehicles…

Continue Reading

WednesdayMar 05, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform

Calidi’s RTNova platform leverages engineered enveloped vaccinia viruses designed for systemic delivery. Calidi’s groundbreaking virotherapy holds “immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors,” says CEO. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies for cancer treatment. Most recently, the company has captured the spotlight for the development of its proprietary systemic platform, RTNova (https://ibn.fm/Z4pM3). The platform represents a significant advancement in systemic virotherapy, particularly in the utilization of enveloped virotherapies to target metastatic tumors across the body. Antitumor virotherapy employs viruses that selectively infect and…

Continue Reading

FridayFeb 28, 2025 12:20 pm

Forschungszentrum Jülich Becomes First High-Performance Computing Center to Own a D-Wave Quantum Inc. (NYSE: QBTS) Advantage System

Forschungszentrum Jülich scientists have already leveraged D-Wave's technology for research on protein folding, electron interactions and quantum physics. The Advantage™ system features over 5,000 qubits and 15-way connectivity, advancing quantum optimization research. The quantum system will be linked to JUPITER, Europe’s first exascale supercomputer, potentially enabling novel computational applications. The system will be upgraded to D-Wave’s next-generation Advantage2™ quantum processor when available, which D-Wave expects will deliver doubled coherence time, higher qubit connectivity and 40% improvement in energy scaling. The collaboration is anticipated to take the use of quantum technology to a new level, according to Prof. Kristel Michielsen, head…

Continue Reading

WednesdayFeb 26, 2025 10:45 am

SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), Viridi Partner on Buffalo, NY Solar and Battery Project

SolarBank and Viridi are collaborating on a 3.06 MW solar and 1.2 MWh battery energy storage system in Buffalo, New York, repurposing a closed landfill, converting unused land into a source of clean energy. Pending approvals and financing, SolarBank is set to begin construction, while Viridi will provide the battery storage system. Viridi's battery systems include integrated fire suppression and anti-propagation technology to enhance safety. Once operational, the project will function under a community solar model, where residents can subscribe to the project, earning credits on their electricity bills without installing personal solar panels. Disseminated on behalf of SolarBank Corporation…

Continue Reading

TuesdayFeb 25, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research

One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts. Calidi’s improved financial footing reassures investors and allows the company to focus on achieving key milestones in its research pipeline. The company has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious AACR annual meeting in April 2025. Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented…

Continue Reading

MondayFeb 24, 2025 1:00 pm

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

According to the American Cancer Society, cancer is the second leading cause of death globally. Oncology drugs are a cornerstone of modern cancer treatment. Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments. Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of research and development, offering hope for millions of patients worldwide.…

Continue Reading

MondayFeb 24, 2025 12:15 pm

SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Reports Substantial Revenue, Gross Profit Growth, with Key Developments Painting Positive Outlook

The company’s six-month revenue reached $20.1 million CAD ($14.15 million USD), reflecting steady long-term growth despite seasonal fluctuations. Gross profit margin increased to 29.2%, up from 18.4% in the prior year, signaling improved margins. Assets surged 372% to $185.3 million CAD ($130.47 million USD) during the six month period, following the acquisition of Solar Flow-Through Funds Ltd. Recent $70.3 million CAD ($49.5 million USD) deal with Qcells will drive revenue in upcoming quarters. Share price more than doubled in early February, signaling investor interest. Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier…

Continue Reading

SaturdayFeb 22, 2025 10:45 am

D-Wave Quantum Inc. (NYSE: QBTS) Qubits 2025 Conference to Showcase ‘Quantum Realized’ Across Scientific Achievements, Technical Advancements and Commercial Applications

D-Wave’s Qubits 2025 quantum computing user conference will be held in Scottsdale, Arizona, March 31 and April 1, as well as a virtual livestream of the first day’s talks. The event will feature presentations from D-Wave executives, customers and industry thought leaders, highlighting product and technical roadmap updates, scientific advancements, the intersection of quantum and AI, and more. Presentations will showcase how the company’s quantum technology is delivering tangible value today. D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first supplier of production-grade quantum computers, announced that its Qubits 2025 quantum computing…

Continue Reading

FridayFeb 21, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors

As cancer numbers grow, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving patient outcomes. Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells while activating the body’s own immune system to attack the tumor. The company’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors. Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and…

Continue Reading

Contact us: (512) 354-7000